Does DACOMITINIB Cause Second primary malignancy? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Second primary malignancy have been filed in association with DACOMITINIB (Vizimpro). This represents 0.9% of all adverse event reports for DACOMITINIB.
6
Reports of Second primary malignancy with DACOMITINIB
0.9%
of all DACOMITINIB reports
1
Deaths
1
Hospitalizations
How Dangerous Is Second primary malignancy From DACOMITINIB?
Of the 6 reports, 1 (16.7%) resulted in death, 1 (16.7%) required hospitalization, and 1 (16.7%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DACOMITINIB. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does DACOMITINIB Cause?
Death (253)
Diarrhoea (114)
Rash (108)
Neoplasm progression (78)
Paronychia (55)
Blood pressure increased (47)
Off label use (35)
Pruritus (34)
Dyspnoea (30)
Carcinoembryonic antigen increased (28)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which DACOMITINIB Alternatives Have Lower Second primary malignancy Risk?
DACOMITINIB vs DACTINOMYCIN
DACOMITINIB vs DALBAVANCIN
DACOMITINIB vs DALFAMPRIDINE
DACOMITINIB vs DALTEPARIN
DACOMITINIB vs DAMOCTOCOG ALFA PEGOL